Skip to content

Impact of 5R Brief Intervention in Reducing Influenza Vaccine Hesitancy: A Randomized Controlled Trial in Elderly Patients

Impact of 5R Brief Intervention in Reducing Influenza Vaccine Hesitancy: A Randomized Controlled Trial in Elderly Patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400079634
Enrollment
Unknown
Registered
2024-01-08
Start date
2024-01-15
Completion date
Unknown
Last updated
2024-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Influenza

Interventions

Intervention group:Reciving health education materials and 5R brief intervention for influenza vaccination
Control group:Reciving health education materials

Sponsors

Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 100 Years

Inclusion criteria

Inclusion criteria: (1) Inpatients or outpatients at the First Affiliated Hospital of Sun Yat-sen University, and voluntarily participate in the survey, follow up, and related health care services; (2) Individuals aged 60 years or above; (3) Individuals with stable health status, or in a stable period of chronic diseases (no need for hospitalization or temporary hospital visits recently); (4) Residents in Guangzhou.

Exclusion criteria

Exclusion criteria: (1) Individuals who are in the acute phase of disease requiring hospitalization at the time of recruitment (e.g., infection, fever, acute exacerbation of chronic disease, surgery, etc.). When the acute disease is stabilized, they can be assessed again for the recruitment; (2) Individuals with severe allergic reactions or other adverse reactions to influenza vaccine previously; (3) Individuals with immunosuppression or other immune system diseases who may not be able to produce an adequate response or are at higher risk for complications; (4) Individuals with severe heart diseases, respiratory diseases, or other conditions that may have higher risk of influenza vaccination; (5) Individuals who have recently administered other vaccines or plan to have other vaccines during the trial; (6) Individuals who are using high-dose corticosteroids or other immunosuppressive drugs.

Design outcomes

Secondary

MeasureTime frame
Influenza incidence rate;Influenza-like illness incidence rate;Influenza vaccine efficacy;

Primary

MeasureTime frame
Influenza vaccination rate;

Countries

China

Contacts

Public ContactLin Xu

Sun Yat-sen University

xulin27@mail.sysu.edu.cn+86 20 8733 5523

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026